{"date":"2025-03-16","count":2,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6499-2025-03-16-2025-10yb8rh","company_id":"6499","company":"益安","market":"上櫃","industry":"生技醫療","date":"2025-03-16","time":"20:25:36","subject":"本公司受邀參加元富證券舉辦之法人說明會","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：益安（6499），2025-03-16 20:25，「本公司受邀參加元富證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6589-2025-03-16-1942-1o53lka","company_id":"6589","company":"台康生技","market":"上市","industry":"生技醫療","date":"2025-03-16","time":"19:42:57","subject":"本公司向阿根廷國家藥物、食品及醫療科技管理局遞交研發中產品EG1206A（pertuzumab生物相似藥）第三期臨床試驗計畫書","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：台康生技（6589），2025-03-16 19:42，「本公司向阿根廷國家藥物、食品及醫療科技管理局遞交研發中產品EG1206A（pertuzumab生物相似藥）第三期臨床試驗」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}